CRISPR-Cas12a/Cas13a在肿瘤分子诊断中的研究进展
本文综述了CRISPR-Cas12a/Cas13a系统在肿瘤分子诊断中的最新进展。Cas12a靶向DNA检测基因突变和DNA甲基化,Cas13a识别RNA直接分析miRNA和病毒RNA,并通过信号转换策略扩展至蛋白质、外泌体等非核酸标志物。文章分析了PAM依赖性、基质干扰、多重检测局限和临床验证缺口等挑战,并讨论了无PAM工程变体、纳米技术、微流控和人工智能整合等未来方向。
要点
- Cas12a检测DNA突变和甲基化,Cas13a检测miRNA和病毒RNA
- CRISPR系统兼容POCT,可扩展至蛋白质和外泌体检测
- 临床转化仍需解决PAM依赖、基质干扰和标准化问题
核心结论
- CRISPR-Cas12a/Cas13a凭借可编程序列识别和稳健信号放大,在肿瘤分子诊断中展现潜力,但临床标准化和验证仍需推进。
研究设计与样本
- 本文为综述,总结CRISPR-Cas12a/Cas13a生物传感器在肿瘤分子诊断中的最新进展。
主要发现
- Cas12a靶向DNA,可敏感检测基因突变和DNA甲基化;Cas13a特异性识别RNA,直接分析miRNA和病毒RNA。
- 通过信号转换策略,CRISPR-Cas12a/Cas13a系统已扩展至蛋白质、外泌体等非核酸生物标志物检测。
临床怎么用
- CRISPR-Cas12a/Cas13a系统兼容POCT,可用于液体活检中低丰度核酸标志物的敏感检测。
局限性
- 当前挑战包括PAM依赖性、基质干扰、多重检测限制和临床验证缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer remains a leading cause of global mortality, with early diagnosis being pivotal for improving treatment outcomes. Traditional tissue biopsy is limited by its invasiveness, inability to capture tumor heterogeneity, and failure to support dynamic monitoring. Liquid biopsy has emerged as a non-invasive alternative, enabling the analysis of circulating tumor biomarkers (e.g., ctDNA, miRNAs, exosomes) in bodily fluids. However, current liquid biopsy technologies (e.g., NGS, ddPCR) suffer from high costs, complex workflows, poor standardization, and insufficient sensitivity for low-abundance biomarkers. The CRISPR-Cas systems, particularly Cas12a and Cas13a, have revolutionized molecular diagnostics due to their programmable sequence recognition, robust signal amplification via trans-cleavage/collateral cleavage activity, and compatibility with point-of-care testing (POCT). Cas12a targets DNA molecules, enabling sensitive detection of gene mutations and DNA methylation, while Cas13a specifically recognizes RNA, facilitating direct analysis of miRNAs and viral RNAs. Additionally, these systems have been extended to non-nucleic acid biomarkers (e.g., proteins, exosomes) through signal conversion strategies. This review summarizes the latest advances in CRISPR-Cas12a/Cas13a-based biosensors for cancer molecular diagnosis, including the detection of gene mutations, epigenetic modifications, miRNAs, tumor-associated viruses, and non-nucleic acid biomarkers. We critically analyze current challenges (e.g., PAM dependence, matrix interference, multiplexing limitations, clinical validation gaps) and discuss future perspectives, such as engineering PAM-less Cas variants, integrating nanotechnology, microfluidics, and artificial intelligence/artificial intelligence (AI), and advancing clinical standardization. This review aims to provide a comprehensive reference for the development and clinical translation of CRISPR-based cancer diagnostic technologies.
引用
- Lin J, Wang Y, Zeng B, et al. CRISPR-Cas12a/Cas13a in cancer molecular diagnosis. Clin Chim Acta. 2026. PMID: 41796733. doi:10.1016/j.cca.2026.120934
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。